ストックスクリーナーアプリを入手
36.78
0.74%
0.27
前日終値:
$36.51
開ける：
$40.57
24時間の取引高:
287.58K
Relative Volume:
0.41
時価総額：
$154.49M
収益：
$32.73M
当期純損益:
$-19.52M
株価収益率:
-6.654
EPS:
-5.5275
ネットキャッシュフロー:
$-24.61M
1週間 パフォーマンス:
+30.15%
1か月 パフォーマンス:
+32.02%
6か月 パフォーマンス:
+240.08%
1年 パフォーマンス:
+54.02%
1日の値動き範囲:
$36.77
$45.50
1週間の範囲:
$28.01
$45.50
52週間の値動き範囲:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
36.78 | 154.49M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-13 | 開始されました | Jefferies | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2022-11-21 | 開始されました | Piper Sandler | Overweight |
| 2022-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-03 | 開始されました | Craig Hallum | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-04-09 | 開始されました | Stifel | Buy |
| 2020-01-28 | 開始されました | BTIG Research | Buy |
| 2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
Form 4 Cue Biopharma For: 10 July By Investing.com - Investing.com India
Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone - Stock Titan
Cue Biopharma (CUE) awards 21,800 restricted stock units to board director - Stock Titan
Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award - Stock Titan
Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant - Stock Titan
Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief - Stock Titan
Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief - Stock Titan
Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package - Stock Titan
Cue Biopharma Announces $50 Million Private Placement - TipRanks
Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle - TradingView
Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs - Stock Titan
Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE) - Seeking Alpha
Cue Biopharma Shares Rise on $50 Million Private Placement Pricing - Moomoo
CUE: Cue Biopharma Secures $50M in Private Placement - GuruFocus
Cue Biopharma (CUE) Secures $50M in Private Placement Financing - GuruFocus
Cue Biopharma to raise $50M in oversubscribed private placement - MSN
CUE BIOPHARMA ANNOUNCES $50.0 MILLION PRIVATE PLACEMENT - Moomoo
Cue Biopharma raises $50M in private placement By Investing.com - Investing.com South Africa
Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs - Stock Titan
Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management - Quiver Quantitative
Cue Biopharma Announces $50.0 Million Private Placement - GlobeNewswire Inc.
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma Inc outlines its immunotherapy approach for long-term investors - ad-hoc-news.de
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Signal Law Group Issues VRS Bulletin on Cue Biopharma, Inc. (CUE) - The Daily Tribune News
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Index - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Index - marketscreener.com
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Price to book forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma(CUE) Stock Options Chain | Quotes & News - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Enterprise value to revenue forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to earnings forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Long term debt to total equity ratio of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lin Shao-Lee - Moomoo
Cue Biopharma Stocklong-term strategy in immuno-oncology - AD HOC NEWS
Cue Biopharma Inc (CUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
CUE BIOPHARMA INC (CUE) Stock Chart - ChartMill
Cue Biopharma (NASDAQ: CUE) registers 551,724 pre-funded-warrant shares for resale - Stock Titan
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cue Biopharma | EFFECT: Others - Moomoo
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Inc (CUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):